article; cancer therapy; cell culture; cell therapy; chimeric antigen receptor T-cell immunotherapy; CHO cell line; drug development; drug industry; drug manufacture; drug safety; gene therapy; gene vector; helper cell; hematologic malignancy; human; human cell; life expectancy; microbial contamination; multiple myeloma; personalized medicine; plasmid; protein expression; quality control; reimbursement; T lymphocyte; vaccination; capsid protein/ec [Endogenous Compound]; DNA helicase/ec [Endogenous Compound]; SARS-CoV-2 vaccine; viral protein/ec [Endogenous Compound]; virus DNA/ec [Endogenous Compound]